The Vaccine Alliance, Gavi, has signed a $5m deal for an Ebola vaccine, to protect against future outbreaks. The deal commits pharmaceutical company Merck to keeping 300,000 vaccines ready for emergency use or further clinical trials. It will also submit an application to license the vaccine by the end of 2017, the next step to prepare a global stockpile.
More than 11,000 people have died in the latest outbreak in West Africa. The sheer scale of the outbreak – the largest in history – led to an unprecedented push on vaccines, which condensed a decade’s work into less than a year.
Merck has led trials of the VSV-EBOV vaccine – which combines a fragment of the Ebola virus with another safer virus in order to train the immune system to beat Ebola. Early evidence from studies in West Africa suggest it may give 100% protection, although more data is still being collected.
Dr Seth Berkley, the chief executive of Gavi, said: "The suffering caused by the Ebola crisis was a wake-up call to many in the global health community.
"New threats require smart solutions, and our innovative financing agreement with Merck will ensure that we are ahead of the curve for future Ebola outbreaks."
Gavi, an alliance of public bodies and companies committed to saving lives through vaccination, announced the advanced-purchase commitment at the World Economic Forum held at Davos in the Swiss Alps.
The $5m paid to Merck will be offset against any vaccines Gavi orders once the shot is licensed.